Document is current
Any future updates will be listed below
-
Authors
Banaschewski, Brandon J. H. https://orcid.org/0009-0007-2047-6451
Michki, Sylvia N. https://orcid.org/0000-0003-0403-0648
Sitaraman, Sneha https://orcid.org/0000-0001-8541-9190
Pan, Ruby https://orcid.org/0000-0002-5202-5280
Wang, Joanna Y.
Stewart, Dominique
Goldy, Mary Kate
Lin, Susan M.
Cantu, Edward
Katzen, Jeremy B.
Basil, Maria C. https://orcid.org/0000-0003-4716-1285
Emtiazjoo, Amir M.
Todd, Jamie L.
Gokey, Jason J.
Kropski, Jonathan A. https://orcid.org/0000-0002-8923-1344
Frank, David B.
Zepp, Jarod A. https://orcid.org/0000-0002-2468-8087
Young, Lisa R. https://orcid.org/0000-0003-3297-8532
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01HL119503, K24HL143281, R01HL155821, R56HL167937, R00HL141684, R35GM146835)
- License Information
-
More Information
Article History
Received: 5 August 2024
Accepted: 21 January 2025
First Online: 22 February 2025
Competing interests
: B.J.B. reports equity in MannKind Corporation. JLT acknowledges grants to the institution from the National Institute of Health, AstraZeneca, Boehringer Ingelheim, and Care Dx; and advisory board participation for Avalyn and Sanofi. E.C. reports consulting fees from CSL Behring and United Therapeutics, and meeting travel support from Pulmocide Ltd. E.C. also reports board participation for the International Society of Heart and Lung Transplantation, regional representative role for the UNOS Lung Committee, and as a consultant for device group for the FDA. J.A.K. reports grants from Boehringer Ingelheim and scientific advisory board membership at APIE and ARDA. L.R.Y. reports scientific advisory board participation for Boehringer Ingelheim and Sanofi and royalties from Wolters Kluwer for UpToDate authorship. All conflicts of interest reported are outside the scope of the submitted work.
